Axa S.A. Merus N.V. Transaction History

Axa S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$12.8 - $23.66 $3.41 Million - $6.3 Million	-266,477 Closed	0 $0
Q3 2022 Feb 14, 2023	BUY	$18.64 - $28.93 $811,045 - $1.26 Million	43,511 Added 19.51%	266,477 $5.34 Million
Q3 2022 Nov 14, 2022	BUY	$18.64 - $28.93 $811,045 - $1.26 Million	43,511 Added 19.51%	266,477 $5.34 Million
Q2 2022 Feb 14, 2023	SELL	$13.98 - $29.25 $60,589 - $126,769	-4,334 Reduced 1.91%	222,966 $5.05 Million
Q2 2022 Aug 15, 2022	SELL	$13.98 - $29.25 $60,589 - $126,769	-4,334 Reduced 1.91%	222,966 $5.05 Million
Q1 2022 Feb 14, 2023	SELL	$23.58 - $30.91 $923,793 - $1.21 Million	-39,177 Reduced 14.7%	227,300 $6.01 Million
Q1 2022 May 13, 2022	SELL	$23.58 - $30.91 $1.18 Million - $1.54 Million	-49,971 Reduced 18.02%	227,300 $6.01 Million
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $64,080 - $103,457	3,204 Added 1.17%	277,271 $8.82 Million
Q3 2021 Nov 15, 2021	BUY	$16.48 - $27.23 $166,365 - $274,886	10,095 Added 3.82%	274,067 $6.03 Million
Q2 2021 Aug 13, 2021	BUY	$20.0 - $25.48 $5.28 Million - $6.73 Million	263,972 New	263,972 $5.56 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.